Evidence map›Paper›PMID 40815370›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2025

An assessment of anti-VEGF drugs safety based on real-world data: from popularity to spontaneous reporting in eudravigilance database.

Chen Li, Mingxuan Chen, Yicheng Lu

Abstract read
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Chen LiDepartment of Ophthalmology, the First Affiliated Hospital of Soochow University, SuZhou, 215006, Jiangsu Province, China. lceye0902@126.com.ORCID http://orcid.org/0009-0003-4968-0430
Mingxuan ChenSchool of Clinical Medicine, Medical College of Soochow University, SuZhou, 215006, Jiangsu Province, China.
Yicheng LuDepartment of Ophthalmology, the First Affiliated Hospital of Soochow University, SuZhou, 215006, Jiangsu Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAnti-vascular endothelial growth factor (VEGF) drugs are the first-line treatment for neovascular age-related macular degeneration (nAMD). This study analyzed four commonly used anti-VEGF drugs, preliminarily compared the search query results for these drugs on Google to assess public interest and analyzed the profile of ocular adverse drug reactions (ADRs) for these drugs in the EudraVigilance (EV) database.

methodsA descriptive retrospective study was conducted. We observed four commonly used anti-VEGF drugs for the clinical treatment of nAMD, with ADR reports sourced from the EV database. Data collected included age, gender, regional distribution, and report origins. We analyzed the overall characteristics of these ADR reports and explored the distribution across 27 System Organ Classes (SOCs) for these drugs. Additionally, we compared the off-label use ratios and severe outcomes of these drugs. Subsequently, we used disproportionality analysis (DPA) to compare the relationship between these drugs and ocular ADRs. Lastly, we compared the most common ocular ADRs among different drugs and the similarities and differences in ocular ADRs.

resultsGoogle Trends indicated that in 2024, the interest scores for the four drugs ranked from highest to lowest were aflibercept, ranibizumab, faricimab, and brolucizumab. As of October 22, 2024, the total number of Individual Case Safety Reports (ICSRs) for the four drugs uploaded in EV was 32,878, with a higher proportion of ADR reported in brolucizumab-treated cases compared to the other three drugs. The age group of 65-85 years reported the highest incidence, and a higher proportion of ADRs occurred in females. Compared to the European Economic Area (EEA), more cases were reported for these drugs in NON-EEA regions, with reports primarily from healthcare professional (HP). Eye disorders were the most frequently reported among the four drugs. The frequency of ADRs reported for off-label use was highest with faricimab, while ranibizumab had a higher number of cases with severe outcomes. DPA revealed that brolucizumab had a significantly higher reporting rate of ocular ADRs compared to the other three inhibitors.

conclusionAnti-VEGF drugs often cause ocular ADRs when treating nAMD, which should be a clinical concern. To reduce the risk of adverse reactions, clinicians should closely monitor patients using these drugs.

Indexed as

Adverse Drug Reaction Reporting SystemsAngiogenesis InhibitorsDrug-Related Side Effects and Adverse ReactionsPharmacovigilanceWet Macular DegenerationAgedAged, 80 and overBevacizumabDatabases, FactualFemaleHumansIncidenceIntravitreal InjectionsMaleMiddle AgedRanibizumabafliberceptAngiogenesis InhibitorsBevacizumabRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AAdverse drug reactionEudraVigilancePharmacovigilanceSpontaneous reportingVascular endothelial growth factorVascular endothelial growth factor inhibitor

Identifiers

PMID40815370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.